Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)

Alterome Therapeutics, Inc. announced the dosing of the first patient in AKTive-001, a Phase I/Ib trial of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.